PL2310034T3 - Peptydy do leczenia beta-amyloidoz - Google Patents

Peptydy do leczenia beta-amyloidoz

Info

Publication number
PL2310034T3
PL2310034T3 PL09761153T PL09761153T PL2310034T3 PL 2310034 T3 PL2310034 T3 PL 2310034T3 PL 09761153 T PL09761153 T PL 09761153T PL 09761153 T PL09761153 T PL 09761153T PL 2310034 T3 PL2310034 T3 PL 2310034T3
Authority
PL
Poland
Prior art keywords
amyloidoses
peptides
treating beta
beta
treating
Prior art date
Application number
PL09761153T
Other languages
English (en)
Inventor
Markus Mandler
Christian Gieffers
Frank Mattner
Andrea Dolischka
Oleksandr Otava
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of PL2310034T3 publication Critical patent/PL2310034T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09761153T 2008-06-12 2009-06-12 Peptydy do leczenia beta-amyloidoz PL2310034T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0095108A AT506819B1 (de) 2008-06-12 2008-06-12 Vakzin zur behandlung von alzheimer-krankheit
PCT/AT2009/000236 WO2009149486A2 (en) 2008-06-12 2009-06-12 Compounds for treating diseases
EP09761153.7A EP2310034B9 (en) 2008-06-12 2009-06-12 Peptides for treating beta-amyloidoses

Publications (1)

Publication Number Publication Date
PL2310034T3 true PL2310034T3 (pl) 2014-08-29

Family

ID=41401982

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09761153T PL2310034T3 (pl) 2008-06-12 2009-06-12 Peptydy do leczenia beta-amyloidoz

Country Status (21)

Country Link
US (2) US8613931B2 (pl)
EP (1) EP2310034B9 (pl)
JP (2) JP2011522841A (pl)
KR (1) KR20110036808A (pl)
CN (1) CN102123727B (pl)
AT (3) AT506819B1 (pl)
AU (1) AU2009257169B2 (pl)
BR (1) BRPI0915137A2 (pl)
CA (1) CA2723991A1 (pl)
CY (1) CY1115316T1 (pl)
DK (1) DK2310034T3 (pl)
ES (1) ES2461492T3 (pl)
HR (1) HRP20140586T1 (pl)
IL (1) IL209895A (pl)
MX (1) MX2010013648A (pl)
PL (1) PL2310034T3 (pl)
PT (1) PT2310034E (pl)
RS (1) RS53236B (pl)
RU (1) RU2553345C2 (pl)
SI (1) SI2310034T1 (pl)
WO (1) WO2009149486A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
US9617302B2 (en) * 2011-06-14 2017-04-11 National Taiwan University Peptide compounds for inhibition of platelet aggregation
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
CA3029676A1 (en) * 2016-06-29 2018-01-04 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3064785A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN109985231A (zh) * 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
CA3167073A1 (en) * 2020-03-10 2021-09-16 Preeti BAKRANIA Cyclic peptides
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
CN116724046A (zh) * 2020-09-17 2023-09-08 欧萨尔普罗席纳有限公司 用于治疗阿尔茨海默病之β淀粉样蛋白疫苗
CN112608926A (zh) * 2020-12-08 2021-04-06 安徽大千生物工程有限公司 一种用于检测β淀粉样蛋白的基因序列组、杂交瘤细胞组及胶乳增强免疫比浊法试剂盒
CN113061161B (zh) * 2021-04-02 2023-09-12 河南省农业科学院动物免疫学重点实验室 靶向amyloid-beta结构的抑制性肽配基及应用
AR127498A1 (es) * 2021-10-28 2024-01-31 Abbvie Inc ANTICUERPOS ANTI-b AMILOIDE Y MÉTODOS DE USO DE LOS MISMOS
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
RU2294211C2 (ru) * 2001-01-19 2007-02-27 Цитос Байотекнолоджи Аг Композиция и способ для иммунизации, способ продуцирования неприродного, упорядоченного и повторяющегося массива антигенов
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005023985A2 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
US20050176030A1 (en) 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US7780963B2 (en) 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
EP2441493B1 (en) * 2006-03-14 2014-05-07 Oregon Health and Science University Methods for producing an immune response to tuberculosis
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
WO2009091518A2 (en) * 2008-01-15 2009-07-23 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits

Also Published As

Publication number Publication date
EP2310034B9 (en) 2014-12-17
US20110097351A1 (en) 2011-04-28
CN102123727B (zh) 2015-06-10
US8613931B2 (en) 2013-12-24
AT509106B1 (de) 2011-12-15
HK1152470A1 (en) 2012-03-02
US20130230545A1 (en) 2013-09-05
RU2553345C2 (ru) 2015-06-10
WO2009149486A2 (en) 2009-12-17
KR20110036808A (ko) 2011-04-11
DK2310034T3 (da) 2014-04-28
ES2461492T3 (es) 2014-05-20
MX2010013648A (es) 2011-04-05
AT509105B1 (de) 2011-12-15
JP6041917B2 (ja) 2016-12-14
EP2310034A2 (en) 2011-04-20
IL209895A0 (en) 2011-02-28
EP2310034B1 (en) 2014-03-26
WO2009149486A3 (en) 2010-06-10
AT509105A1 (de) 2011-06-15
JP2011522841A (ja) 2011-08-04
PT2310034E (pt) 2014-06-05
AT506819A1 (de) 2009-12-15
RS53236B (sr) 2014-08-29
RU2011100126A (ru) 2012-07-20
AU2009257169B2 (en) 2015-06-25
CN102123727A (zh) 2011-07-13
CY1115316T1 (el) 2017-01-04
AT506819B1 (de) 2011-06-15
CA2723991A1 (en) 2009-12-17
IL209895A (en) 2015-09-24
HRP20140586T1 (hr) 2014-09-12
SI2310034T1 (sl) 2014-05-30
BRPI0915137A2 (pt) 2016-02-16
AT509106A1 (de) 2011-06-15
AU2009257169A1 (en) 2009-12-17
JP2015147771A (ja) 2015-08-20

Similar Documents

Publication Publication Date Title
PT2310034E (pt) Péptidos para o tratamento de beta-amiloidoses
IL257418A (en) Methods for treating addiction
IL213619A0 (en) Treatment
GB0806419D0 (en) Process
GB0802116D0 (en) Treatment
GB0822011D0 (en) Treatment
GB0803669D0 (en) Process
GB0801580D0 (en) Process
GB0801209D0 (en) Process
GB0920981D0 (en) Peptides
GB0811992D0 (en) Treatment
GB0800875D0 (en) Process
GB0816976D0 (en) Protein
GB0802201D0 (en) Treatment system
GB0807161D0 (en) Process
GB0803960D0 (en) Process
GB0820972D0 (en) Treatment
GB0808357D0 (en) Process
GB0920987D0 (en) Peptides
GB0805912D0 (en) Treatment
GB0823273D0 (en) Treatment system
GB0803663D0 (en) Process
GB0817978D0 (en) Peptides
GB0818627D0 (en) Protein
GB0808359D0 (en) Process